A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma.

Trial Profile

A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Fluticasone furoate (Primary) ; Vilanterol/fluticasone furoate (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 May 2016 Results (post hoc analysis, n = 2019) assessing proportion of subjects achieving the minimal clinically important difference for improvement in ACQ score presented at the 112th International Conference of the American Thoracic Society.
    • 09 Jan 2012 Primary endpoint 'Time-to-exacerbation-of-symptoms' has been met, according to a GlaxoSmithKline and Theravance media release.
    • 07 Oct 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top